Cobimetinib

Cotellic (cobimetinib) is a small molecule pharmaceutical. Cobimetinib was first approved as Cotellic on 2015-11-10. It is used to treat melanoma in the USA. It has been approved in Europe to treat melanoma. The pharmaceutical is active against dual specificity mitogen-activated protein kinase kinase 1 and dual specificity mitogen-activated protein kinase kinase 2. In addition, it is known to target dual specificity mitogen-activated protein kinase kinase 7 and serine/threonine-protein kinase B-raf. Cotellic's patents are valid until 2036-06-30 (FDA).